A securities class action has been filed against PROCEPT BioRobotics Corporation in the United States District Court for the Northern District of California over allegations that an undisclosed discount program encouraged bulk handpiece orders beyond procedure demand. Robbins LLP is reminding investors who purchased or acquired PROCEPT common stock between February 28, 2024, and February 25, 2026, inclusive, that they must seek appointment as lead plaintiff by September 22, 2026. The complaint alleges that the program pulled forward U.S. handpiece sales and revenue, widened the gap between orders and procedures, and contributed to more than 10,000 excess units in customer inventories by the end of the Class Period. It also claims PROCEPT overstated handpiece sales and field-System utilization, concealed operational and financial risks, and issued 2025 handpiece sales and revenue guidance without a reasonably achievable factual basis. The stock fell from $27.84 on February 25, 2026, to $22.69 on February 27, a decline of more than 18%, and later fell below $18 by July 22, 2026. No class has been certified, and investors may retain counsel, remain absent class members, or seek lead-plaintiff status without that status determining eligibility for any potential recovery.